Skip to content
10-Q

Quarterly Report

ACADIA PHARMACEUTICALS INC ACAD

0000950170-25-066231

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 167.36M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $302.53M
Current Liabilities Q1 2025 · Dec 31, 2024 $394.87M
Total Liabilities Q1 2025 · Mar 31, 2025 $367.13M
Total Liabilities Q1 2025 · Dec 31, 2024 $454.96M
Current Assets Q1 2025 · Mar 31, 2025 $870.94M
Current Assets Q1 2025 · Dec 31, 2024 $938.32M
Total Assets Q1 2025 · Mar 31, 2025 $1.13B
Total Assets Q1 2025 · Dec 31, 2024 $1.19B
Shares Diluted Q1 2025 · Mar 31, 2024 166.62M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 $29.08M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $204.75M
Cash And Equivalents Q1 2025 · Dec 31, 2023 $188.66M
Stockholders Equity Q1 2025 · Mar 31, 2024 $464.04M
Stockholders Equity Q1 2025 · Dec 31, 2023 $431.76M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.10
Eps Basic Q1 2025 · Mar 31, 2024 $0.10
Sga Expense Q1 2025 · Mar 31, 2024 $107.99M
Rd Expense Q1 2025 · Mar 31, 2024 $59.68M
Net Income Q1 2025 · Mar 31, 2024 $16.56M
Operating Income Q1 2025 · Mar 31, 2024 $15.21M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $22.95M
Revenue Q1 2025 · Mar 31, 2024 $205.83M